- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | BIODESIX INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 27.01. | Hedge Fund and Insider Trading News: Seth Klarman, Dan Loeb, Michael Burry, Michael Platt, Bridgewater Associates, Greenlight Capital, Biodesix Inc (BDSX), UWM Holdings Corp (UWMC), and More | 4 | Insider Monkey | ||
| BIODESIX Aktie jetzt für 0€ handeln | |||||
| 13.01. | Biodesix stock soars as preliminary results exceed guidance, achieves EBITDA profitability | 4 | Investing.com | ||
| 12.01. | Biodesix Surges On Strong Preliminary Q4 And FY2025 Revenue Results | 5 | RTTNews | ||
| 12.01. | Biodesix skyrockets 43%, expects FY revenue to beat guidance | 4 | Seeking Alpha | ||
| 12.01. | Biodesix reports 41% revenue growth in Q4, exceeds 2025 guidance | 3 | Investing.com | ||
| 12.01. | Biodesix, Inc.: Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) | 152 | GlobeNewswire (Europe) | Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025.... ► Artikel lesen | |
| 03.12.25 | Biodesix, Inc.: Biodesix to Present New Data at Two Major Upcoming Scientific Meetings | 2 | GlobeNewswire (USA) | ||
| 04.11.25 | Biodesix: Canaccord bestätigt Kaufempfehlung nach starken Q3-Zahlen | 2 | Investing.com Deutsch | ||
| 04.11.25 | Biodesix stock maintains Buy rating at Canaccord after strong Q3 results | 1 | Investing.com | ||
| 04.11.25 | Biodesix raises 2025 revenue guidance to $84M-$86M as primary care expansion accelerates | 4 | Seeking Alpha | ||
| 03.11.25 | Biodesix GAAP EPS of -$1.16 beats by $0.35, revenue of $21.8M beats by $0.82M | 1 | Seeking Alpha | ||
| 03.11.25 | Biodesix, Inc.: Biodesix Announces Third Quarter 2025 Results and Highlights | 128 | GlobeNewswire (Europe) | Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million... ► Artikel lesen | |
| 03.11.25 | BIODESIX INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11.25 | BIODESIX INC - 8-K, Current Report | - | SEC Filings | ||
| 31.10.25 | What's Next: Biodesix's Earnings Preview | 2 | Benzinga.com | ||
| 30.10.25 | Biodesix, Inc.: Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 22.10.25 | Biodesix stock rises after expanded Bio-Rad partnership | 1 | Investing.com | ||
| 22.10.25 | Biodesix to validate ESR1 mutation test for advanced breast cancer | 1 | Investing.com | ||
| 22.10.25 | Biodesix validiert ESR1-Mutationstest für fortgeschrittenen Brustkrebs | 1 | Investing.com Deutsch |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 43,170 | -0,70 % | Ionos, Kontron, Lanxess, Qiagen, Redcare Pharmacy, Siltronic, TeamViewer: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| VALNEVA | 3,986 | +0,61 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,910 | 0,00 % | HEIDELBERG PHARMA AG zeigt klare Stärke im Trend | ||
| OCUGEN | 1,150 | +1,05 % | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical... ► Artikel lesen | |
| MAINZ BIOMED | 0,945 | -4,51 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung 2026 | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Konferenz
Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,745 | -1,29 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity | Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed
VK2735 Currently Being Evaluated in... ► Artikel lesen | |
| INFLARX | 0,730 | -2,54 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,320 | -0,53 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TEMPUS AI | 46,600 | 0,00 % | Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones | ||
| GENMAB | 263,50 | +0,84 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for 2025 | Company Announcement Net sales of DARZALEX- in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,430 | -0,14 % | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
Halle (Saale) / Munich, Germany, January 7, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon)... ► Artikel lesen | |
| EDITAS MEDICINE | 1,536 | +0,03 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 5,392 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 | ||
| DYNAVAX | 13,085 | -0,19 % | Laufende Fusionskontrollverfahren: Sanofi S.A., Paris/FR; mittelbarer Erwerb eines Mehrheitsanteils und alleiniger Kontrolle über die Dynavax Technologies Corporation, Delaware/USA | Datum der Anmeldung:05.01.2026Aktenzeichen:B3-21/26Unternehmen:Sanofi S.A., Paris/FR; mittelbarer Erwerb eines Mehrheitsanteils und alleiniger Kontrolle über die Dynavax Technologies Corporation, Delaware/USAProduktmärkte:monovalenter... ► Artikel lesen |
Das Unternehmen BIODESIX INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 10,450 Euro und damit +4,92 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODESIX INC finden Sie auf Wallstreet Online.